Novavax (NVAX) News Today $7.58 +0.85 (+12.63%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$7.54 -0.04 (-0.58%) As of 08/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Novavax Up Today?Toggle Visibility of Why Is Novavax Up Today?Novavax, Inc. (NVAX) shares moved today after the company reported stronger-than-expected second-quarter results, received a key milestone payment, and raised its full-year outlook. Positive Sentiment: Second-quarter revenue of $239 million topped estimates, driven by a $175 million milestone payment tied to U.S. approval of its COVID-19 vaccine. Novavax beats quarterly revenue estimates on milestone payment Positive Sentiment: Adjusted EPS of $0.62 beat the consensus loss estimate of ($0.07), marking the company’s return to profitability as costs declined and product revenues rose. Novavax Q2 Earnings and Revenues Top Estimates Positive Sentiment: The company raised its full-year revenue guidance after beating Q2 forecasts and expects stronger Nuvaxovid™ sales, prompting a pre-market rally. Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales Positive Sentiment: FDA granted BLA approval for Nuvaxovid™, triggering a $175 million milestone payment from Sanofi and transferring U.S. commercial leadership for the 2025–26 season. Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights Positive Sentiment: Early Phase 3 data for its COVID-19/influenza combination and standalone flu vaccines showed robust immune responses, outperforming a Fluzone HD comparator. Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights Neutral Sentiment: Analysts maintain a consensus “Hold” rating on NVAX, with eight brokerages covering the stock. Novavax, Inc. Given Consensus Rating of "Hold" by Analysts Neutral Sentiment: Investors will hear more details on today’s conference call at 8:30 a.m. ET following the Q2 release. Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights Neutral Sentiment: Prior to results, NVAX attracted preview coverage from Seeking Alpha and GuruFocus, highlighting its shift from losses to profitability. Novavax Q2 2025 Earnings Preview Negative Sentiment: Q2 revenue declined 42.4% year-over-year despite beating estimates, reflecting lower COVID-19 vaccine volumes compared to 2024. View Press Release Posted 5h agoAI Generated. May Contain Errors. NVAX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Decoding Novavax Inc (NVAX): A Strategic SWOT Insight2 hours ago | gurufocus.comQ2 2025 Novavax Inc Earnings Call Transcript3 hours ago | gurufocus.comNovavax (NVAX) Profit Jumps on MilestoneAugust 6 at 6:13 PM | fool.comNovavax (NVAX) Reports Q2 Progress and Key Partnership DevelopmentsAugust 6 at 5:13 PM | gurufocus.comNovavax Ups Outlook, Eyes Stronger Nuvaxovid SalesAugust 6 at 11:05 AM | benzinga.comNovavax Reports Second Quarter 2025 Financial Results and Operational Highlights | NVAX Stock NewsAugust 6 at 10:01 AM | gurufocus.comNovavax Inc (NVAX) Q2 2025 Earnings: EPS of $0.62 Beats Estimate, Revenue Surges to $239 MillionAugust 6 at 10:01 AM | gurufocus.comNovavax (NVAX) Surpasses Earnings Expectations with Revenue BoostAugust 6 at 10:01 AM | gurufocus.comNovavax Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 6 at 10:01 AM | gurufocus.comNovavax (NVAX) Raises Revenue Forecast Amid Strong Vaccine PartnershipsAugust 6 at 10:01 AM | gurufocus.comNovavax (NVAX) Boosts 2025 Revenue Outlook Amid Strategic CollaborationsAugust 6 at 10:01 AM | gurufocus.comNVAX Earnings: Novavax Stock Rallies on Upbeat Annual Revenue ForecastAugust 6 at 9:32 AM | tipranks.comNovavax beats quarterly revenue estimates on milestone paymentAugust 6 at 8:08 AM | reuters.comNovavax Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 6 at 8:00 AM | prnewswire.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by AnalystsAugust 6 at 2:48 AM | marketbeat.comNovavax (NVAX) Prepares for Q2 Earnings Report Amid Earnings HistoryAugust 5 at 1:43 PM | gurufocus.comNovavax Q2 2025 Earnings PreviewAugust 5 at 12:42 PM | seekingalpha.comJupiter Asset Management Ltd. Takes $1.91 Million Position in Novavax, Inc. (NASDAQ:NVAX)August 5 at 4:47 AM | marketbeat.comNovavax (NVAX) Projected to Post Quarterly Earnings on WednesdayAugust 1, 2025 | marketbeat.comNovavax poised to end in red for seventh straight sessionAugust 1, 2025 | seekingalpha.comNovavax Stock Dips As Moderna's Woes Weigh On Vaccine SectorAugust 1, 2025 | benzinga.comBayforest Capital Ltd Takes $404,000 Position in Novavax, Inc. (NASDAQ:NVAX)August 1, 2025 | marketbeat.comNovavax to Report Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | prnewswire.comNovavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical StudyJuly 25, 2025 | finanznachrichten.deNovavax stock rises after promising H5N1 vaccine preclinical resultsJuly 25, 2025 | investing.comNovavax Sees Unusually Large Options Volume (NASDAQ:NVAX)July 24, 2025 | marketbeat.comNovavax's H5N1 vaccine shows promise with single-dose optionJuly 24, 2025 | investing.comNovavax Shares Promising Results For Bird Flu Vaccine, Tested In PrimatesJuly 24, 2025 | benzinga.comNovavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical StudyJuly 24, 2025 | prnewswire.comBank of America Lowers Novavax (NASDAQ:NVAX) Price Target to $9.00July 22, 2025 | marketbeat.comNovavax (NVAX) Price Target Lowered by B of A Securities | NVAX Stock NewsJuly 22, 2025 | gurufocus.comHussman Strategic Advisors Inc. Grows Stock Position in Novavax, Inc. (NASDAQ:NVAX)July 19, 2025 | marketbeat.comNovavax Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 17, 2025 | marketwatch.comNovavax (NVAX) Rises Higher Than Market: Key FactsJuly 15, 2025 | msn.com45,000 Shares in Novavax, Inc. (NASDAQ:NVAX) Purchased by DekaBank Deutsche GirozentraleJuly 15, 2025 | marketbeat.comBTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PTJuly 13, 2025 | insidermonkey.com13 Cheap Stocks with Huge Upside PotentialJuly 12, 2025 | insidermonkey.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Hold" by BrokeragesJuly 12, 2025 | marketbeat.comDespite Revenue Jump, Novavax Appears Immune To Long-Term GrowthJuly 11, 2025 | seekingalpha.com2 Beaten-Down Stocks That Haven't Hit Rock Bottom YetJuly 11, 2025 | fool.comCiti Initiates Coverage of Novavax (NVAX) With a Sell RatingJuly 10, 2025 | insidermonkey.comNovavax (NASDAQ:NVAX) Trading 7.7% Higher - Here's What HappenedJuly 8, 2025 | marketbeat.comVontobel Holding Ltd. Lowers Position in Novavax, Inc. (NASDAQ:NVAX)July 8, 2025 | marketbeat.comNovavax Inc. Research & Ratings | NVAX - Barron'sJuly 6, 2025 | barrons.comNovavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comRFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine ApprovalJuly 3, 2025 | benzinga.comRFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientistsJuly 3, 2025 | fortune.comVaccines and antibodies up for debate at CDC advisory panel meetingJune 26, 2025 | reuters.comNovavax, Inc. (NVAX) latest stock news and headlines - Yahoo FinanceJune 25, 2025 | uk.finance.yahoo.comNovavax Shareholders Approve Key Proposals at Annual MeetingJune 24, 2025 | tipranks.com Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address NVAX Media Mentions By Week NVAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVAX News Sentiment▼0.500.42▲Average Medical News Sentiment NVAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVAX Articles This Week▼2111▲NVAX Articles Average Week Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Ocugen News Vaxart News Johnson & Johnson News Pfizer News Ligand Pharmaceuticals News Amicus Therapeutics News BioCryst Pharmaceuticals News Celldex Therapeutics News Dynavax Technologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVAX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVAX Stock Alerts